Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26975378 | 0.89 | GAA (0.56) | GAAKMT2AMEN1TDP1NLRP3 | |
| SCHEMBL31055722 | 0.88 | ACHE (0.41) | GAANLRP3GSTO1 | |
| SCHEMBL31055720 | 0.88 | GAA (0.39) | GAANLRP3GSTO1 | |
| SCHEMBL22460320 | 0.88 | GAA (0.52) | GAAKMT2AMEN1TDP1NLRP3 | |
| SCHEMBL31055704 | 0.87 | GSTO1 (0.39) | GAANLRP3GSTO1 | |
| SCHEMBL31055694 | 0.87 | MEN1 (0.39) | GAAKMT2AMEN1NLRP3GSTO1 | |
| SCHEMBL31055702 | 0.87 | KCNT1 (0.41) | GAANLRP3GSTO1 | |
| SCHEMBL7567422 | 0.85 | MEN1 (0.56) | KMT2AMEN1TDP1NLRP3 | |
| SCHEMBL22460158 | 0.83 | GSTO1 (0.41) | GAANLRP3GSTO1 | |
| SCHEMBL7572034 | 0.83 | MEN1 (0.58) | KMT2AMEN1TDP1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416948-B1 | INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS | UNIV QUEENSLAND (AU) | 2024-07-24 | — | — | EP | claimed |
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-02 | — | — | US | disclosed |
| US-20200299284-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | NLRP3, NOD1, PYCARD | GAA 2604/4885KMT2A 3753/4885MEN1 2219/4885 |
| US-20200299284-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, NOD1, PYCARD | GAA 2604/4885KMT2A 3753/4885MEN1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.